INB03 for the Treatment of Pulmonary Complications From COVID-19
Trial details
- Registry ID
- NCT04370236
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
Also recorded as DN-TNF, XPro1595, XENP345, Quellor
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| INB03 for the Treatment of Pulmonary Complications From COVID-19NCT04370236 | INMB | Phase 2, Phase 3 | Terminated | 2021-10-13Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |